“Amgen knows how to do it right in Korea”

By Eo, Yun-Ho | translator Byun Kyung A

21.03.24 12:40:01

가나다라 0

“All products launched after opening the Korean office have been listed, now to expand coverage”

“No plan for downsizing the Korean office, continuing to engage with the labor union”

Amgen knows the game in the industry. Besides the title of the ‘Number One Global Bio Company,’ Amgen Korea knows how to be versatile in South Korea.

Since opening the South Korean office in 2015, Amgen listed all six products—antiarthritis Prolia (denosumab) and Evenity (romosozumab), skeletal-related events preventing drug Xgeva (denosumab), high cholesterol treatment Repatha (evolocumab), acute lymphoblastic leukemia (ALL) treatment Blincyto (blinatumomab) and multiple myeoloma treatment Kyprolis (carfilzomib)—for the National Health Insurance (NHI) reimbursement.

Considering the NHI system, listing each product was not the easiest job. However, Amgen Korea’s determ

Eo, Yun-Ho(unkindfish@dailypharm.com)

If you want to see the full article, please JOIN US (click)